UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): December 23, 2005 (December 19, 2005)

REGENERON PHARMACEUTICALS, INC.

New York		000-19034		133444607
(State or other		(Commission File Number)		(I.R.S. Employer
jurisdiction of				Identification Number)
incorporation)

777 Old Saw Mill River Road, Tarrytown, New York	10591-6707
(Address of principal executive offices)	(Zip Code)

(914) 347-7000
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 1.01		Entry into a Material Definitive Agreement

On December 19, 2005, the Compensation Committee of the Board of Directors of Regeneron Pharmaceuticals, Inc. (the “Company”) approved the following 2006 annual salaries and year-end 2005 cash bonus awards (paid in January 2006) to the specified named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission) of the Company:

		Name/Title		2006 Salary (% increase from 2005)				Cash Bonus
		Leonard S. Schleifer, M.D., Ph.D.		$	685,000	(2.9%)		$	340,000
		President & Chief Executive Officer
		George D. Yancopoulos, M.D., Ph.D.		$	544,300	(4.5%)		$	280,000
		Executive Vice President, Chief
		Scientific Officer and President,
		Regeneron Research Laboratories
		Murray A. Goldberg		$	374,300	(5.0%)		$	179,700
		Senior Vice President, Finance
		& Administration, Chief Financial
		Officer, Treasurer, and Assistant Secretary
		Neil Stahl, Ph.D.		$	348,400	(4.5%)		$	139,400
		Senior Vice President, Preclinical
		Development and Biomolecular Science
		Randall G. Rupp, Ph.D.		$	339,100	(4.5%)		$	125,500
		Senior Vice President, Manufacturing
		Operations

     Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.